Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HT-003
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Hoth Therapeutics
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Details : The 1-year agreement extension is based on positive results generated from the prior research agreement that support a therapeutic effect of HT-003 in key signaling pathways contributing to the development of acne.
Product Name : HT-003
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 28, 2021
Lead Product(s) : HT-003
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Hoth Therapeutics
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Biohaven Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Dr. Richard Granstein, M.D., Chairman of Dermatology at Weill Cornell Medicine in New York City, will initiate an investigator-led clinical trial with a Biohaven CGRP-receptor antagonist for the treatment of plaque psoriasis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 16, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Biohaven Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : 9-Valent HPV Vaccine Recombinant
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : The Division of Cancer Treatment and Diagnosis
Deal Size : $8.3 million
Deal Type : Funding
Weill Cornell Medicine secured funding HIV and HPV Prevention
Details : The grant will fund work designing and implementing three clinical trials that focus on two forms of cancer that are associated with HPV, which is a sexually transmitted infection.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
February 14, 2020
Lead Product(s) : 9-Valent HPV Vaccine Recombinant
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : The Division of Cancer Treatment and Diagnosis
Deal Size : $8.3 million
Deal Type : Funding